Skip to content
Open access

DESIGN, SYNTHESIS, MOLECULAR DOCKING, AND IN VITRO ANTICANCER EVALUATION OF NOVEL IMIDAZOLEBASED SCHIFF BASE DERIVATIVES AS ESTROGEN RECEPTOR-TARGETED AGENTS

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 4 references

Abstract

: The development of new and efficient therapeutic agents is necessary because breast cancer continues to be one of the major causes of cancer-related death globally. This study used integrated computational and experimental methods to create and assess a number of Schiff base derivatives based on imidazole as possible inhibitors of estrogen receptors. Strong binding affinities between -9.0 and -9.3 kcal/mol were revealed by molecular docking investigations against the estrogen receptor (PDB ID: 6CHZ) utilizing AutoDock Tools. Through hydrophobic interactions and hydrogen bonding with important active site residues, the compounds showed stable ligand–receptor interactions. The MTT test was employed to evaluate the synthesized compounds' antitumor effectiveness in vitro against MCF-7 breast cancer cell lines. Their antiproliferative capability was confirmed by the results, which showed considerable dose-dependent cytotoxicity. Analysis of the structure–activity relationship (SAR) revealed proposed that the imidazole scaffold's electron-withdrawing substituents improve biological activity and binding affinity. Overall, the results show that these Schiff base derivatives based on imidazole may be interesting lead molecules for estrogen receptor-targeted breast cancer therapy, necessitating more pharmacokinetic and in vivo testing.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.